Oxaborole backup (HAT)
• Target disease: HAT
• Partners: Anacor, USA;Scynexis, USA; Pace University, USA
• Management: Discovery & Preclinical Director, Robert Don; Head of Drug Discovery: Charles Mowbray; Project Coordinator: Stéphanie Braillard
• Project start: April 2007
• Funding: Department for International Development (DFID), UK; Médecins Sans Frontières/Doctors without Borders, International; Spanish Agency for International Development Cooperation (AECID), Spain; Swiss Agency for Development and Cooperation (SDC), Switzerland
Objective: Profile potential back-up candidates for SCYX-7158 for the treatment of HAT
Oxaboroles are unique boron-containing compounds with antiparasitic activities that were originally provided by Anacor, USA. This project aims to develop a backup compound in the oxaborole class that could rapidly replace SCYX-7158 in case it fails clinical development.
Potential backups have been identified and profiled in vivo for efficacy and the most advanced compounds selected for exploratory toxicity and further PK studies. The objective is to present an optimized candidate in this series by the end of 2012.
Last update: December 2012
Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License